Temozolomide in malignant gliomas: current use and future targets.
Cancer Chemother Pharmacol
; 64(4): 647-55, 2009 Sep.
Article
em En
| MEDLINE
| ID: mdl-19543728
ABSTRACT
Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug. When combined with radiotherapy in patients with newly diagnosed glioblastoma, survival is significantly prolonged. This finding has led to widespread use of TMZ for patients with this disease. We summarize developing concerns regarding the use of TMZ, imaging of malignant gliomas, and the pharmacology of TMZ-mechanism of action, scheduling and strategies for overcoming resistance.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Encefálicas
/
Antineoplásicos Alquilantes
/
Dacarbazina
/
Glioma
Limite:
Humans
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article